THAR Tharimmune, Inc.: Operatsion rentabellik

THAR (tharimmune.com) - kompaniyaning tovar belgisi

Antitellar patentlari tufayli yuzaga kelgan yuqori kirish to'siqlari Tharimmune, Inc. (THAR) kompaniyasining bozor barqarorligini belgilaydi. Tarixiy operatsion marja darajalari ushbu holatni tasdiqlaydi, bunda 0.00 qiymati eng so'nggi ko'rsatkichni ifodalaydi. Ushbu tendentsiya jigar patologiyalari uchun qichishish terapiyasining muvaffaqiyatiga asoslangan, uzoq muddatli o'sish esa makroiqtisodiy tebranishlardan mustaqillikka va klinik sinovlarning borishiga bog'liq.

Tharimmune Inc (THAR): Sotuvning operatsion marjasi 21.02.2024dan 18.02.2026gacha

Tharimmune, Inc. (THAR) kompaniyasining tahliliy kesimlari

- aksiya narxi va baholash bo'yicha konsensus prognoz:
Kompaniyaning fundamental tahlili:Tharimmune Corp
Tharimmune Corporation asosiy tovari

Investorlar Tharimmune, Inc. (THAR) moliyaviy barqarorligini soliqlar va foizlar to'lanishidan oldin, operatsion xarajatlar qoplanib qolganidan keyin qolgan daromad qismi orqali baholashlari lozim. Operatsion foyda marjasini tahlil qilishda, tijorat daromadlarining yo'qligi va laboratoriya xarajatlari ushbu ko'rsatkichni manfiy qilganiga e'tibor berish muhimdir, bu esa antitelolarning klinik sinovlari kengayishi bilan birlik xarajatlarning oshishini aks ettiradi.

Tharimmune, Inc. raqobatchilari tahlili

Operatsion rentabellik BeiGene Ltd|Halozyme Therapeutics - Operatsion foyda marjasi|Sotuvning operatsion marjasi RVMD (Revolution Medicines Corp)|Operatsion foyda koeffitsiyenti AAPG|Operatsion rentabellik CG Oncology Therapeutics CGON|Operatsion foyda normasi URGN|BCAX: Sotuvning operatsion marjasi|PSNL: Operatsion rentabellik|Erasca (ERAS) - Operatsion rentabellik|DCTH - Operatsion faoliyat rentabelligi|YMAB (Y-mAbs Corp) - Operatsion marja|Sotuvning operatsion marjasi Aura Biosciences (AURA)|Operatsion rentabellik Candel Therapeutics Inc. (CADL)|Sotuvning operatsion marjasi Accuray, Inc. ARAY|Operatsion rentabellik sellaslifesciences.com SLS|Operatsion foyda normasi ACTU|CTOR - Operatsion rentabellik|Operatsion faoliyat rentabelligi tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Operatsion rentabellik|FATE: Operatsion foyda koeffitsiyenti|WHWK (Aadi Bioscience, Inc.) - Operatsion marja|TCRX (TScan Therapeutics) - Operatsion foyda koeffitsiyenti|Operatsion rentabellik Champions Oncology (CSBR)|Operatsion faoliyat rentabelligi XBiotech USA|Operatsion rentabellik CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Sotuvning operatsion rentabelligi|RADX - Operatsion rentabellik|ARTV - Operatsion marja|Adlai Nortye Ltd (ANL) - Operatsion rentabellik|Veru Pharma - Operatsion foyda normasi|Operatsion rentabellik Tempest Therapeutics Corp|Operatsion foyda bo'yicha sotuv rentabelligi XLO (Xilio Therapeutics, Inc.)|Operatsion marja RENB|MURA (Mural Oncology) - Operatsion foyda normasi|Operatsion marja KAPA (Kairos Pharma Ltd)|OKUR: Operatsion foyda bo'yicha sotuv rentabelligi|GDTC: Sotuvning operatsion marjasi|CRIS - Operatsion marja|APLM: Operatsion marja|Sotuvning operatsion marjasi Advanced Biomed Inc.|Sotuvning operatsion marjasi GNPX|Operatsion foyda bo'yicha sotuv rentabelligi CLDI (Calidi Biotherapeutics)|Operatsion marja SBFM|Xenetic Biosciences, Inc. - Operatsion foyda bo'yicha sotuv rentabelligi|Operatsion rentabellik Salarius Pharmaceuticals SLRX|Operatsion marja purple-biotech.com PPBT|AONC - Operatsion rentabellik|BGNE: Operatsion rentabellik|CKPT: Operatsion marja|Elevation Oncology - Operatsion foyda normasi|ICAD (iCAD) - Operatsion marja|IKNA: Operatsion foyda normasi|Operatsion rentabellik Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operatsion foyda normasi|Operatsion rentabellik MorphoSys Corporation MOR|NAYA: Operatsion foyda bo'yicha sotuv rentabelligi|Ascentage Pharma Group International - Operatsion marja